AbbVie Gets Accelerated Public Reimbursement Approval Of Epkinly In Nine Canadian Provinces
Monday announced that nine provinces have approved accelerated public coverage of Epkinly, a treatment for adult ...
AbbVie Falters Despite Progress in Lymphoma Treatment
AbbVie (NYSE: ABBV) today announced that nine provinces have provided accelerated public coverage of EPKINLY™. EPKINLY is a treatment for adult patients with Relapsed or Refractory diffuse large ...
Nine Provinces Approve Accelerated Public Reimbursement of Diffuse Large B-Cell Lymphoma Treatment Under New Early Access Process
AbbVie (NYSE: ABBV), today announced that nine (9) provinces have provided accelerated public coverage of EPKINLY™. EPKINLY is a treatment for adult patients with Relapsed or Refractory diffuse large ...
Genmab A/S (GMAB): Leading Innovation in Antibody Therapeutics
However, on October 11, the CME FedWatch tool showed that 89.5% of the market now expects a 25 bps rate cut and the rest ...
Genmab’s Strong Performance and Strategic Positioning: A Buy Rating with $50 Price Target
Analyst Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Genmab (GMAB – Research Report) and keeping the price target at ...
Las Cruces Sun-News10d
NMSU football play-caller Tyler Wright’s social media contains dozens of racist, sexist posts
Editor's note: This report contains potentially disturbing and offensive language. New Mexico State football offensive coordinator and quarterbacks coach Tyler Wright's social media contains more ...
Investing16d
Genmab stock growth seen as Darzalex hits peak sales, Redburn optimistic
This growth is anticipated to be driven primarily by Darzalex and another product, Epkinly. The company, however, is preparing to confront a significant revenue gap post-patent expiration. Analyst ...
Cancer Therapy Advisor17d
FDA Clears Cologuard Plus for Colorectal Cancer Screening
Cologuard Plus is expected to be available next year. The US Food and Drug Administration (FDA) has approved the Cologuard Plus test for colorectal cancer screening in adults age 45 years and ...
10 Stocks with Biggest Upside Potential According to Hedge Funds
In this article, we will discuss the 10 Stocks with Biggest Upside Potential According to Hedge Funds. The US equities saw a ...
2minutemedicine.com23d
AbbVie’s novel epkinly results in meaningful treatment response in patients with treatment-refractory lymphoma
Epkinly showed an overall response rate of 82% with 62.5% of patients achieving complete response. 65% of patients had grade 1-2 cytokine release syndrome (CRS), though severe cases (grade 3) were ...
Targeted Oncology23d
Later-Line CD19 and Bispecific Therapies Considered After CAR T
We currently have 2 FDA-approved bispecific antibodies in the third-line setting for relapsed/refractory DLBCL [with epcoritamab (Epkinly) and glofitamab (Columvi), along with loncastuximab in the ...